ReviewFrontiers in oncology2025
The advances of DNA methylation in the liquid biopsy for the detection of lung cancer.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Clinical and translational roles of circulating tumor cells in non-small cell and small cell lung cancer: a narrative review.Journal of thoracic disease · 2026Review
- Epigenetic profiling of circulating cell-free DNA for early detection and minimal residual disease assessment in lung cancer: a focus on DNA methylation.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is the most common cancer in the world and the leading cause of cancer death. The absence of effective early detection is one of the major contributors to high mortality rate of lung cancer. Liquid biopsy has the potential to become as a new method for early detection of cancer due to its non-invasive nature, ease of access, and overall presentation of tumor. Liquid biopsy has garnered increasing attention for its role in early detection and tumor genome assessment through the examination of circulating tumor DNA (ctDNA) released by apoptotic or necrotic tumor cells. DNA methylation is a potential biomarker for liquid biopsy due to its early onset, cancer specificity, biological stability, and accessibility in bodily fluids. This review aims to present an overview of the process of DNA methylation, identify potential methylation gene targets, and explore the application of liquid biopsy in the detection of lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.